Document is current
Any future updates will be listed below
-
Authors
Soeda, Ikumi
Shibata, Masahiro https://orcid.org/0000-0003-1028-2796
Inaishi, Takahiro
Ichikawa, Takahiro
Sugino, Kayoko
Kanaya, Emi
Kanda, Mitsuro
Hayashi, Masamichi
Masuda, Norikazu
-
Funding
Funding for this research was provided by:
Nagoya University
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 14 April 2025
First Online: 2 May 2025
Declarations
:
: Norikazu Masuda received a research grant from Chugai Pharma, Eli Lilly Japan, AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Eisai, Novartis, Gilead Sciences, and Ono Pharma; received lecture fees from Chugai Pharma, Pfizer, AstraZeneca, Eli Lilly Japan, Daiichi Sankyo, and Eisai; and is a board representative of the Japan Breast Cancer Research Group (JBCRG) and a board member of the Japanese Breast Cancer Society (JBCS), the Japan Society of Clinical Oncology (JSCO), and the Japan Association of Breast Cancer Screening (JABCS), all without remuneration. The other authors declare no competing interests.
: The present study was approved by the Institutional Review Board and Ethics Committee of Nagoya University Hospital (approval no. 2019‑0028). Informed consent was obtained from all patients included in the study.
: The participants provided written informed consent for publication as required by the Institutional Review Board and Ethics Committee of Nagoya University Hospital.
